A clinical decisions support system provides personalized treatment recommendations on lowering cardiovascular risk factors in patients with schizophrenia, schizoaffective disorder, and bipolar disorder.
The approval was supported by data from two phase 3 studies that evaluated Caplyta as monotherapy and adjunctive therapy with lithium or valproate in adults with bipolar depression.
Lybalvi is an atypical antipsychotic comprised of samidorphan co-formulated with olanzapine in a single bilayer tablet.
The approval was based on data from 27 clinical studies, including the phase 3 ENLIGHTEN-1 and ENLIGHTEN-2 studies.
In both trials, BXCL501 demonstrated statistically significant, rapid and durable improvements vs placebo across multiple agitation scales.
ALKS 3831 is composed of samidorphan, a mu-opioid receptor antagonist, which is co-formulated with the established antipsychotic agent, olanzapine, in a single bilayer tablet.
Sleep abnormalities and cognition in bipolar disorder may be related, and may affect cognition in this patient population.
Among patients with borderline personality disorder, symptom severity was associated with less stability and lower relative amplitude. Impulsivity and mood instability were each negatively correlated with interdaily stability and relative amplitude.
Compared with the general population, patients with bipolar disorder have an increased risk of developing idiopathic Parkinson disease.
A family history of illness in prior generations may be related to an earlier age at onset of bipolar disease.
